Merck & Co., Inc. (NYSE:MRK) Lowered to Hold Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Merck to “Hold” from “Buy,” though the broader analyst consensus remains “Moderate Buy” with an average price target of $151.32.
• Merck’s shares opened at $144.02, near the upper end of their 52-week range, while quarterly results beat expectations with revenue of $16.61 billion and an EPS loss narrower than forecast.
• Insiders sold nearly $30 million of stock during the last quarter, while institutional investors own 76.07% of the company; analysts remain focused on Merck’s pipeline and efforts to reduce reliance on Keytruda ahead of its 2028 patent challenges.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday, Wall Street Zen reports.

Several other research firms have also weighed in on MRK. Royal Bank Of Canada lowered Merck & Co., Inc. from an "outperform" rating to a "sector perform" rating and upped their price target for the company from $142.00 to $150.00 in a research report on Thursday, August 20th. Morgan Stanley upgraded Merck & Co., Inc. from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $116.00 to $179.00 in a research report on Thursday, August 20th. Barclays lifted their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Guggenheim upped their target price on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday. Finally, JPMorgan Chase & Co. increased their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Seventeen analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $151.32.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $144.02 on Friday. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $156.92. The company has a 50-day moving average of $136.51 and a two-hundred day moving average of $124.40. The stock has a market cap of $355.33 billion, a price-to-earnings ratio of 115.22, a PEG ratio of 6.30 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm's revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP David Williams sold 52,847 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock valued at $29,977,783 in the last quarter. Corporate insiders own 0.17% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MRK. California State Teachers Retirement System raised its holdings in Merck & Co., Inc. by 12,537.4% during the second quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company's stock valued at $62,286,552,000 after buying an additional 480,884,635 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock worth $29,169,479,000 after acquiring an additional 1,073,507 shares in the last quarter. State Street Corp boosted its stake in shares of Merck & Co., Inc. by 1.6% during the 4th quarter. State Street Corp now owns 120,040,168 shares of the company's stock worth $12,737,504,000 after acquiring an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock valued at $6,307,572,000 after acquiring an additional 249,110 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: HSBC raised its price target for Merck (MRK) from $150 to $172 and maintained a “Buy” rating, implying substantial upside from the recent share price. Benzinga analyst update
• Positive Sentiment: Guggenheim also increased its Merck price target to $170, reinforcing the view that the company’s pipeline, newer medicines and potential cancer-drug combinations can support growth beyond Keytruda. Guggenheim increases Merck price target
• Positive Sentiment: Merck is expanding its development pipeline and commercial portfolio to reduce reliance on Keytruda ahead of its 2028 patent and exclusivity challenges. This provides a longer-term growth narrative, although execution and successful launches remain important. Merck pipeline and new drugs
• Neutral Sentiment: Merck’s stock attracted significant investor attention, but the coverage offers limited new fundamental information. Separately, broader pharmaceutical discussion highlighted manufacturing hurdles for personalized cancer vaccines and risks surrounding confidential industry information. Merck and cancer-vaccine risks
• Negative Sentiment: Investors remain concerned that Merck’s valuation looks demanding relative to its growth rate and to faster-growing peers such as Eli Lilly. Those concerns, combined with the future Keytruda revenue gap, likely contributed to the recent weakness despite higher analyst targets. Merck valuation versus Eli Lilly

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck's pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.